BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

  1. Hamoda, H.
  2. Davis, S.R.
  3. Cano, A.
  4. Morris, E.
  5. Davison, S.
  6. Panay, N.
  7. Lumsden, M.A.
  8. Hillard, T.
  9. Simoncini, T.
Journal:
Post Reproductive Health

ISSN: 2053-3705,  2053-3691

Year of publication: 2021

Volume: 27

Issue: 1

Pages: 49-55

Type: Letter

DOI: 10.1177/2053369120983154 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus